"It’s interesting to reflect that the industry brought five different vaccines in record time, all of those based on a certain degree of innovation (...). Next time around, we have to be lucky again that somebody else has invested in some science that is ready to be used. We also scaled up manufacturing in record time, so that billions of doses were basically available for the whole world. (...)
Still, there is a political agenda in the Western world to feel maybe some sort of bad conscience and they are proposing to waver IP rights in future situations. I get a bit emotional because I think this is politics at its worst, as it’s not helping anyone. It’s actually destroying the incentive to make the next version of vaccine or cure we all need."
The EU’s ambitious goals to protect cancer patients could transform lives and save millions more. A properly-implemented...
Read more
Animal use and welfare in pharmaceutical R&D
The pharmaceutical industry is committed to responsible animal use, with tangible outcomes leading to improved animal welfare and high-quality science. Check our report for a list of over 70 examples of 3Rs (Replace, Reduce, Refine) in action.
War, COVID-19 pandemic and vulnerability of supply chains are pushing the EU to be more resilient and self-sufficient...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.